Mangoceuticals, Inc. Common Stock (MGRX) - Total Assets
Based on the latest financial reports, Mangoceuticals, Inc. Common Stock (MGRX) holds total assets worth $14.17 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Mangoceuticals, Inc. Common Stock - Total Assets Trend (2021–2025)
This chart illustrates how Mangoceuticals, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Also see MGRX market cap overview for the company's overall valuation and market capitalisation.
Mangoceuticals, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Mangoceuticals, Inc. Common Stock's total assets of $14.17 Million consist of 9.6% current assets and 90.4% non-current assets. Review how much debt does Mangoceuticals, Inc. Common Stock carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $14.23 Million | 88.5% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Mangoceuticals, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Mangoceuticals, Inc. Common Stock stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mangoceuticals, Inc. Common Stock's current assets represent 9.6% of total assets in 2025, a decrease from 100.0% in 2021.
- Cash Position: Cash and equivalents constituted 9.2% of total assets in 2025, down from 100.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 88.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 88.5% of total assets.
Mangoceuticals, Inc. Common Stock Competitors by Total Assets
Key competitors of Mangoceuticals, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
TRELLUS HEALTH LS -0006
F:85Q
|
Germany | €9.22 Million |
|
ARTRYA Ltd
AU:AYA
|
Australia | AU$92.19 Million |
|
Painchek Ltd
AU:PCK
|
Australia | AU$7.63 Million |
|
Intrasense
PA:ALINS
|
France | €7.99 Million |
|
Trivarx Ltd
AU:TRI
|
Australia | AU$16.53 Million |
|
HITIQ Ltd
AU:HIQ
|
Australia | AU$3.28 Million |
|
Pro Medicus Ltd
AU:PME
|
Australia | AU$533.91 Million |
|
Cogstate Ltd
AU:CGS
|
Australia | AU$64.77 Million |
Mangoceuticals, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.18 | 0.07 | 0.01 |
| Quick Ratio | 0.18 | 0.07 | 0.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.15 Million | $-1.48 Million | $-138.33K |
Mangoceuticals, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Mangoceuticals, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.72 |
| Latest Market Cap to Assets Ratio | 0.56 |
| Asset Growth Rate (YoY) | 4.7% |
| Total Assets | $16.09 Million |
| Market Capitalization | $8.97 Million USD |
Valuation Analysis
Below Book Valuation: The market values Mangoceuticals, Inc. Common Stock's assets below their book value (0.56x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Mangoceuticals, Inc. Common Stock's assets grew by 4.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Mangoceuticals, Inc. Common Stock (2021–2025)
The table below shows the annual total assets of Mangoceuticals, Inc. Common Stock from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $16.09 Million | +4.68% |
| 2024-12-31 | $15.37 Million | +1362.75% |
| 2023-12-31 | $1.05 Million | +4.74% |
| 2022-12-31 | $1.00 Million | +4349.17% |
| 2021-12-31 | $22.55K | -- |
About Mangoceuticals, Inc. Common Stock
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also p… Read more